Tp. Haverty et al., OKT3 MONOCLONAL-ANTIBODY TREATMENT OF STEROID-RESISTANT LIVER-TRANSPLANT REJECTION, Current therapeutic research, 55(4), 1994, pp. 382-395
Citations number
45
Categorie Soggetti
Pharmacology & Pharmacy","Medicine, Research & Experimental
Since the initial report of the use of murine monoclonal antibody OKT3
for treatment of acute renal rejection, a significant body of informa
tion has been collected regarding the efficacy of OKT3 in reversing ac
ute rejections in kidney, liver, and cardiac transplant recipients. Th
is study retrospectively analyzes the efficacy of OKT3 therapy for the
treatment of steroid-resistant hepatic rejection. Treatment with OKT3
reversed acute hepatic rejection in 109 (83%) of 131 patients. Comple
te reversal was achieved in 59 (45%) of 131 patients and partial rever
sal in 50 (38%) of 131 patients. At 1 year, graft and patient survival
were 72% and 69%, respectively. No significant differences were noted
in reversal rate and in 12-month graft and patient survival rates bet
ween patients experiencing one rejection episode and those experiencin
g two or more rejection episodes. As expected, adverse events were com
mon in the first days of therapy but were well tolerated in most patie
nts.